MRI and C-11-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma

摘要

Purpose: Normalization of tumor vasculature after administering bevacizumab (BEV) makes assessment of therapeutic response using MRI difficult. The aim of this study was to clarify whether PET with C-11-methyl-L-methionine (MET-PET) would supplement MRI assessing of response after initiating BEV in glioblastoma.